Stock price when the opinion was issued
(A Top Pick May 3/16. Down 95%.) This was a mistake. There are shareholder lawsuits involved. It was growth by acquisition, and it looks like they dramatically overpaid for some assets. They got involved with generic competition, and as well, the perfect storm of politics of the last election really killed the stock.
This has grown by acquisition, buying a lot of drugs. They sell drugs to over 100 companies. Generates EBITDA of around $600 million. Have $3.5 billion of debt. They free cash flow $300 million a year which they can pay down the debt with. Thinks there is a very good chance this company will not be public in a couple of weeks. Dividend yield of 1.14%.